News Event
FDA Approves new Obesity Drug- Locraserin
Posted Date: 5/17/2012 9:27:00 AM

The U.S. Food and Drug Administration''s Endocrinologic and Metabolic Drugs Advisory Committee has approved Arena Pharmaceuticals'' and Eisai''s new obesity drug Lorcaserin. Word came from the FDA on May 10 and both Arena and Eisai say they''re thrilled to continue developing the drug. Locraserin is an investigational drug that provides weight loss and maintenance to people who are clinically overweight and obese. The drug acts as a selective serotonin 2C receptor agonist, according to a press release. "The advisory committee''s positive vote supports our belief in lorcaserin as a potential new treatment option for the medical management of overweight and obesity," said Jack Lief, Arena''s President and Chief Executive Officer. "We will continue to work with the FDA as the agency completes its review of the lorcaserin new drug application." Visit:

Follow medcarpet on Twitter Facebook: medcarpet
  Job Seeker Login

  Employer Zone

  Post Resume - FREE
Fields marked * are mandatory.
*Upload Resume / CV

Word or Text file upto 350 KB.

*Your Email ID

  I accept Terms of Use and Privacy Policy
  Job Seeker Services
  Get jobs in your inbox
Set your own criteria to receive relevant jobs in your inbox without registering on Medcarpet.
Create a new Job Alert
  News & Events
FDA Approves new Obesity Drug- Locraserin ...
Efforts being made to strenghten Medical Education ...

click for more »